27 October 2020: Review Paper
Prognosis and Treatment of Liver Transplant Recipients in the COVID-19 Era: A Literature Review
Ashraf Imam 1ADEFG* , Sadi A. Abukhalaf 1ABCDEF* , Hadar Merhav 1CDFG , Samir Abu-Gazala 1ABDG , Oded Cohen-Arazi 1BCEG , Alon Josef Pikarsky 1DEFG , Rifaat Safadi 2EFG** , Abed Khalaileh 1AEFG***DOI: 10.12659/AOT.926196
Ann Transplant 2020; 25:e926196
Table 7 Management and outcomes of the 22 reported liver transplant patients infected with COVID-19.
| Variable | Value |
|---|---|
| Baseline Immunosuppression | |
| Tacrolimus | 15/22 (68.2%) |
| Mycophenolate mofetil | 10/22 (45.5%) |
| Prednisone | 4/22 (18.2%) |
| Azathioprine | 1/22 (4.5%) |
| Everolimus | 3/22 (13.6%) |
| Ciclosporin | 1/22 (4.5%) |
| Management | |
| Immunosuppression | |
| Held tacrolimus | 2/14 (14.3%) |
| Reduced tacrolimus | 2/14 (14.3%) |
| No change tacrolimus | 4/14 (28.6%) |
| Held mycophenolate mofetil | 1/14 (7.1%) |
| Reduced mycophenolate mofetil | 2/14 (14.3%) |
| Prednisone | No change 2 |
| Azathioprine | No change 1 |
| Everolimus | Held 2 |
| Ciclosporin | No change 1 |
| Other Tx | |
| Lopinavir/Ritonavir | 4/14 (28.6%) |
| Hydroxychloroquine | 6/14 (42.9%) |
| Azithromycin | 1/14 (7.1%) |
| Oseltamivir | 2/14 (14.3%) |
| Antibiotics | 5/14 (35.7%) |
| Intravenous methylprednisolone | 3/14 (21.4%) |
| Intravenous immunoglobulin | 2/14 (14.3%) |
| Interferon a,b | 4/14 (28.6%) |
| Tocilizumab | 1/14 (7.1%) |
| ICU admission | 4/14 (28.6%) |
| Outcomes | |
| Clinically recovered/discharged | 16/22 (72.7%) |
| Illness days duration (median, range) | 17 (6–53) |
| Alive but suffers/In hospital | 3/22 (13.6%) |
| Illness days duration (median) | 16 |
| Death | 3/22 (13.6%) |
| Illness days duration (median, range) | 24 (7–45) |